Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777490 | 0.85 | GRM4 (0.56) | GRM4BLMWRNARABCC9 | |
| SCHEMBL7477235 | 0.75 | PDK1 (0.57) | GRM4ALDH1A1 | |
| SCHEMBL4900667 | 0.73 | GRM4 (0.59) | GRM4BLMWRNARABCC9 | |
| SCHEMBL21919186 | 0.73 | GRM4 (0.44) | GRM4BLMWRNARABCG2 | |
| SCHEMBL7230707 | 0.73 | GRM4 (0.44) | GRM4BLMWRNARCNR2 | |
| SCHEMBL19190440 | 0.72 | GRM4 (0.50) | GRM4BLMWRNARCNR2 | |
| SCHEMBL3554749 | 0.72 | ALDH1A1 (0.63) | GRM4BLMWRNALDH1A1 | |
| SCHEMBL3957937 | 0.71 | GRM4 (0.42) | GRM4KCNH2ALDH1A1 | |
| SCHEMBL3173181 | 0.70 | GRM4 (0.48) | GRM4BLMWRNARABCG2 | |
| SCHEMBL3008351 | 0.70 | GRM4 (0.56) | GRM4BLMWRNARKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| US-7153960-B2 | Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1467984-A4 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | ZHOU JIACHENG | 2005-11-03 | — | — | US | disclosed |
| US-6919451-B2 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1467984-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027186-A1 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | F2, TFPI, TFPI2 | GRM4 3878/4885BLM 3122/4885WRN 2773/4885 |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | GRM4 4673/4885BLM 3082/4885WRN 3315/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | GRM4 3423/4885BLM 4305/4885WRN 4081/4885 |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | F2, TFPI, TFPI2 | GRM4 3878/4885BLM 3122/4885WRN 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.